Press Releases

First quarter revenue grew 9% to $64.5 million Consumer revenue grew 17% year over year due to the addition of telehealth revenue On track to achieve FY2023 financial guidance SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co.

SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2023 (FY2023) first quarter after the market closes on Monday,

Achieved FY2022 financial guidance Fourth quarter and full year revenues of $101 million and $272 million representing 14% and 11% increases over prior year, respectively New genomic health services expected in FY2023 Webcast today, May 26, 2022, at 4:30 p.m.

SUNNYVALE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) fourth quarter and full year after the market closes on

SUNNYVALE, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company with a mission to help people access, understand, and benefit from the human genome, today announced that it will present data related to its

SUNNYVALE, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be presenting at the Cowen

SUNNYVALE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be presenting at the Citi

Third quarter revenue of $57 million  Therapeutics group advances first wholly-owned immuno-oncology antibody into clinical trials  Vision of genetics-based primary care offers potential for millions of people to live healthier lives SUNNYVALE, Calif., Feb.

SUNNYVALE, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) third quarter after the market closes on Thursday, February

GSK extends exclusive target discovery period of collaboration for a fifth year to discover and validate novel drug targets using  23andMe’s proprietary genetic and health survey database 23andMe elects for royalty option as GSK advances immuno-oncology antibody  collaboration program targeting